Search Results for "ATTRv"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Vutrisiran: HELIOS-B

Standard response letter on vutrisiran and the HELIOS-B study, a phase 3 study evaluating the efficacy and safety of vutrisiran in patients with the cardiomyopathy of ATTR, including both hATTR and wtATTR.

HELIOS-A: 9-Month Results from the Randomized Treatment Extension Period of Vutrisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

Gene Silencing Therapeutics in Cardiology: A Review Article

Vutrisiran: Randomized Treatment Extension Period of the HELIOS-A Study

Standard response letter on vutrisiran and results from a 9-month analysis of the randomized treatment extension period of HELIOS-A.

Vutrisiran: Pain in Extremity

Standard response letter on vutrisiran and the adverse event of pain in extremity.

Musculoskeletal manifestations in patients with ATTR amyloidosis: Evidence from real-world analyses and clinical trials

Vutrisiran: Dyspnea

Standard response letter on vutrisiran and the adverse event of dyspnea.

APOLLO-B, a Study of Patisiran in Patients with Transthyretin Cardiac Amyloidosis: Primary Long-term Results from the Open-label Extension Period

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.